Immitra Bio raises CHF 2.4 million to advance its in-vivo gene editing platform
Life sciences
3 August 2026
The team at Immitra Bio develops in-vivo gene editing therapies designed as off-the-shelf treatments that work regardless of a patient’s underlying mutation. | © Immitra Bio
Immitra Bio, based in Plan-les-Ouates in the canton of Geneva, has closed an upsized CHF 2.4 million pre-seed round to advance its scalable in-vivo gene editing platform and its lead candidate for an inherited anemia.
Immitra Bio has completed an upsized pre-seed financing round of CHF 2.4 million. CHF 2.25 million came from venture capital and private investors, with a further CHF 150,000 secured through non-dilutive funding. The round was led by Backbone Ventures and co-led by OCCIDENT, with participation from Another VC, Kickfund, Venture Kick, Zürcher Kantonalbank, FONGIT, the ETH Foundation and private investors.
The company is developing a platform for one-time curative in-vivo gene editing therapies, combining a mutation-agnostic gene editing technology with a digital target identification platform. The approach is designed to avoid the complex ex-vivo cell manipulation, patient conditioning and stem cell transplantation required by current gene editing therapies, and to produce off-the-shelf formulations able to treat all patients with a given disease regardless of the underlying mutation.
Proceeds will primarily support preclinical proof-of-concept studies for IB-003, the company’s lead candidate and a potential one-time curative treatment for an inherited anemia. The financing will also fund discovery and validation work across the company’s pipeline, enabled by its digital target discovery platform, as well as continued refinement of the platform itself.
